The medical device company reported strong sales growth in the first four months of the year, with its clinical and research businesses performing well. The firm's financial position also improved, with net cash increasing.
The healthcare company has announced the date and details for its 2025 Annual General Meeting.
The healthcare company has received a notification of a change in major shareholding.
The retailer has announced a director has purchased additional shares in the company.
The healthcare company has responded to a Rule 2.8 announcement by Keensight Capital, confirming that Keensight will not make a firm offer for the Company. The Company has also decided to discontinue its Private Sale Process.
The healthcare company has issued new shares to its executive team as part of a bonus plan.
The medical device company reported a 14% revenue increase and 21% adjusted EBITDA growth in 2024. With strong performance across all regions and a new product launch on the horizon, the outlook remains positive despite some tax-related challenges.
The healthcare company has reported changes in director shareholdings.
The healthcare company has announced a change in shareholding, with Danske Bank A/S now holding 3.43% of the voting rights.
The medical device company confirms it has received a revised proposal from Keensight Capital regarding a possible cash offer, but discussions remain at a preliminary stage.